DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
86.45
+1.77 (2.09%)
At close: Sep 15, 2026, 4:00 PM EDT
86.57
+0.12 (0.14%)
Pre-market: Sep 16, 2026, 7:10 AM EDT
DexCom Revenue
DexCom had revenue of $1.31B in the quarter ending June 30, 2026, with 13.08% growth. This brings the company's revenue in the last twelve months to $4.97B, up 15.54% year-over-year. In the year 2025, DexCom had annual revenue of $4.66B with 15.60% growth.
Revenue (ttm)
$4.97B
Revenue Growth
+15.54%
P/S Ratio
6.57
Revenue / Employee
$447,676
Employees
11,100
Market Cap
32.62B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.66B | 629.00M | 15.60% |
| Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
| Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
| Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
| Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
| Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
| Dec 31, 2019 | 1.48B | 444.40M | 43.08% |
| Dec 31, 2018 | 1.03B | 313.10M | 43.58% |
| Dec 31, 2017 | 718.50M | 145.20M | 25.33% |
| Dec 31, 2016 | 573.30M | 171.30M | 42.61% |
| Dec 31, 2015 | 402.00M | 142.80M | 55.09% |
| Dec 31, 2014 | 259.20M | 99.20M | 62.00% |
| Dec 31, 2013 | 160.00M | 60.10M | 60.16% |
| Dec 31, 2012 | 99.90M | 23.60M | 30.93% |
| Dec 31, 2011 | 76.30M | 27.70M | 57.00% |
| Dec 31, 2010 | 48.60M | 18.91M | 63.67% |
| Dec 31, 2009 | 29.69M | 19.86M | 201.82% |
| Dec 31, 2008 | 9.84M | 5.21M | 112.62% |
| Dec 31, 2007 | 4.63M | 2.46M | 113.23% |
| Dec 31, 2006 | 2.17M | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GE HealthCare Technologies | 21.27B |
| Boston Scientific | 21.00B |
| Koninklijke Philips | 20.18B |
| Zimmer Biomet Holdings | 8.51B |
| Edwards Lifesciences | 6.51B |
| Smith & Nephew | 6.30B |
| STERIS | 6.04B |
| Bio-Rad Laboratories | 2.59B |
DXCM News
- 1 day ago - Dexcom Promotes Jereme Sylvain to Chief Operating Officer - Business Wire
- 5 days ago - Dexcom Appoints Glenn Boehnlein to Board of Directors - Business Wire
- 6 days ago - DexCom Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 8 days ago - Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 13 days ago - Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services - Barrons
- 14 days ago - Dexcom Announces Upcoming Conference Presentation - Business Wire
- 6 weeks ago - Dexcom raises annual revenue forecast on strong demand for glucose monitors - Reuters
- 6 weeks ago - DexCom Earnings Call Transcript: Q2 2026 - Transcripts